Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02263508
Title MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Amgen
Indications

melanoma

Therapies

Pembrolizumab

Talimogene laherparepvec

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.